Latest news with #JazzPharmaceuticals
Yahoo
4 hours ago
- Business
- Yahoo
Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy' Rating
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is included in our list of the 10 Most Undervalued Foreign Stocks to Buy According to Analysts. A closeup of pills in a pharmacy, representing the high quality medications of the company. Despite early-year challenges, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) remains a 'Buy'. On July 22, 2025, Morgan Stanley maintained its 'Buy' rating on JAZZ. However, the analyst lowered its price target slightly from $166 to $165. The analyst attributes its bullish stance to its expectation that the company will bounce back in the second half of the year, following a 10% miss in its Q1 net product sales. This expectation is driven by an extra shipping week in the Oncology segment, stronger demand for Rylaze due to pediatric protocol shifts, and seasonal strength in sleep disorder medication. Meanwhile, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is expected to experience major clinical developments with HERIZON-GEA-01 data and the anticipated dordaviprone FDA decision. Furthermore, the upcoming leadership change boosts optimism. Looking ahead, the analyst's oncology revenue estimate exceeds the street's estimates. On the other hand, Wells Fargo reinforced this outlook, maintaining a 'Buy' rating on July 18 with a price target of $170. Operating in the United States, Europe, and other global markets, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes pharmaceutical products. It remains on our list of the most undervalued stocks. While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds. Disclosure: None.
Yahoo
14-07-2025
- Business
- Yahoo
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 11, the company presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where it outlined its strategic growth initiatives and acknowledged various challenges. A close up of cannabis plants growing in an outdoor facility, symbolizing the product of the cannabinoid company. According to the presentation, Jazz Pharmaceuticals reported robust growth in its neuroscience segment, particularly with Xywav (for sleep disorders like narcolepsy and idiopathic hypersomnia) and Epidiolex (for epilepsy). These products showed 'strong growth' in the first quarter of 2025. Xywav's low sodium content and flexible dosing were highlighted as key market advantages. The company detailed that it is expanding its oncology portfolio and pipeline, which now accounts for over half of its 2024 revenue, up from 26% in 2018. Key oncology initiatives include Zanidatamab (Ziihera), Zepzelca (lurbinectedin), Subzelca (formerly JZP-351), and Dordavapril (from Chimerix acquisition). The company stated that beyond marketed products, it is advancing its pipeline with upcoming product launches and regulatory decisions anticipated to drive future growth. This includes the orexin program (JZP-441 trials being monitored for cardiovascular effects) and prasinezumab in Europe. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) expanded its footprint into the cannabis sector with the acquisition of GW Pharmaceuticals. Consequently, it develops and markets FDA-approved drugs that contain purified cannabis-based substances, specifically cannabidiol (CBD), to treat serious illnesses. While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Returns and 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
07-07-2025
- Business
- Yahoo
Jazz Pharmaceuticals' Ziihera Receives Conditional European Approval for Advanced Biliary Tract Cancer
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential. On July 2, Jazz Pharmaceuticals announced that the European Commission/EC had granted conditional marketing authorization for its new bispecific antibody, called Ziihera (zanidatamab), for the treatment of biliary tract cancer/BTC. The approval extends to all European Union member states, as well as Norway, Iceland, and Liechtenstein. Ziihera is authorized as a single agent for adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) BTC who have previously received at least one line of systemic therapy. The recommended dose for zanidatamab is 20mg/kg, administered intravenously every two weeks, until disease progression or unacceptable toxicity. A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. . The EC's decision was supported by data from the Phase IIb HERIZON-BTC-01 trial, which included 87 participants with previously treated, locally advanced or metastatic HER2-positive BTC. The continuation of this conditional approval depends on further clinical benefits being demonstrated in the ongoing Phase III HERIZON-BTC-302 trial. Jazz Pharmaceuticals (NASDAQ:JAZZ) identifies, develops, and commercializes pharmaceutical products in the US, Europe, and internationally. While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.


Forbes
07-07-2025
- Business
- Forbes
Is JAZZ Stock Undervalued At $110?
POLAND - 2025/02/22: In this photo illustration, the Jazz Pharmaceuticals company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aimed at advanced HER2-Positive Biliary Tract Cancer. Ziihera is the first HER2-targeted therapy approved in the EU for this condition, with anticipated peak annual sales surpassing $2 billion. The stock's poor performance can primarily be linked to a revised earnings forecast for 2025, which has been adjusted downward from $22.50-$24 to $4-$5.60, due to a $1.1 billion impact from one-time IPR&D charges associated with the $935 million Chimerix acquisition along with some litigation costs. Despite this, we consider Jazz Pharmaceuticals to be undervalued at $110, offering an attractive buying opportunity for investors with a 3-5 year investment outlook. That being said, if you are looking for upside potential with less volatility compared to individual stocks, the Trefis High-Quality portfolio offers an alternative, having outperformed the S&P 500 and generated returns over 91% since its inception. Additionally, see – Should You Buy Oscar Health Stock At $17? Trailing Adjusted P/E: At $110, Jazz trades at only 5.5 times its trailing adjusted earnings of $20.19 per share, which is well below its four-year average P/E ratio of 8.1x. For further valuation metrics, examine – Jazz Pharmaceuticals Valuation Ratios. At $110, Jazz trades at only 5.5 times its trailing adjusted earnings of $20.19 per share, which is well below its four-year average P/E ratio of 8.1x. For further valuation metrics, examine – Jazz Pharmaceuticals Valuation Ratios. Future Earnings Potential: While 2025 earnings will be affected by one-off costs, 2026 earnings are anticipated to bounce back to $21.56. While 2025 earnings will be affected by one-off costs, 2026 earnings are anticipated to bounce back to $21.56. Pipeline Contribution: The Chimerix acquisition introduces dordaviprone to the oncology portfolio, with a peak annual sales potential over $500 million. The Chimerix acquisition introduces dordaviprone to the oncology portfolio, with a peak annual sales potential over $500 million. Analyst Consensus: The typical analyst price forecast of $188 suggests a substantial upside potential of 70%. High Debt Load: Jazz Pharmaceuticals has a considerable debt level of $5.4 billion with a market capitalization of $6.7 billion (as of July 3, 2025), leading to a Debt-to-Equity Ratio of 81.6%, which is significantly above the S&P 500 average of 19.4%. A lower debt-to-equity ratio is generally preferred. Jazz Pharmaceuticals has a considerable debt level of $5.4 billion with a market capitalization of $6.7 billion (as of July 3, 2025), leading to a Debt-to-Equity Ratio of 81.6%, which is significantly above the S&P 500 average of 19.4%. A lower debt-to-equity ratio is generally preferred. Historical Underperformance in Downturns: Historically, the stock has performed worse than the S&P 500 during market declines, such as the 2022 inflation shock (JAZZ down 38.7% versus S&P 500 down 25.4%) and the 2020 crisis (JAZZ down 42.6% versus S&P 500 down 33.9%). The stock has also yet to return to its pre-inflation crisis levels. Our dashboard on Buy or Sell JAZZ Stock has more details. Historically, the stock has performed worse than the S&P 500 during market declines, such as the 2022 inflation shock (JAZZ down 38.7% versus S&P 500 down 25.4%) and the 2020 crisis (JAZZ down 42.6% versus S&P 500 down 33.9%). The stock has also yet to return to its pre-inflation crisis levels. Our dashboard on Buy or Sell JAZZ Stock has more details. Slowing Oncology Portfolio Growth: There are specific concerns about a potential slowdown in the growth of the oncology portfolio. Despite the recent revisions to earnings and existing debt concerns, Jazz Pharmaceuticals offers a compelling value proposition. Its robust underlying fundamentals, appealing valuation metrics, and significant future sales potential from Ziihera and dordaviprone indicate that the current stock price does not adequately reflect its intrinsic value. While investors should remain aware of the substantial debt and historical sensitivity to market downturns, the long-term prospects for Jazz Pharmaceuticals seem positive for those with a 3-5 year investment horizon. However, there is always a significant risk associated with investing in a single stock or just a few stocks. Consider the Trefis High Quality (HQ) Portfolio which comprises 30 stocks and has a proven track record of consistently outperforming the S&P 500 over the past four years. Why is that? On the whole, HQ Portfolio stocks delivered superior returns with lower risk as compared to the benchmark index; experiencing less volatility, as evidenced by HQ Portfolio performance metrics .


Reuters
30-06-2025
- Business
- Reuters
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout
June 30 (Reuters) - ASL Strategic Value Fund on Monday urged shareholders of Avadel Pharmaceuticals (AVDL.O), opens new tab to replace its board, citing mismanagement in the rollout of the drugmaker's flagship sleep disorder drug Lumryz since its launch two years ago. The hedge fund said Avadel was unable to convert patients to its drug Lumryz from its rivals, despite the treatment being what it called "best-in-class", leaving hundreds of millions in potential revenue unrealized. Lumryz, which competes with Jazz Pharmaceuticals' (JAZZ.O), opens new tab treatments, is approved in the United States to treat certain symptoms of narcolepsy by using a central nervous system depressant drug called sodium oxybate. ASL said "constant mis-steps" with the launch of Lumryz and miscommunication over the last several years with investors had destroyed significant shareholder value along with the management's credibility. ASL said Avadel should have converted 40% to 50% of sodium oxybate users within two years of launching Lumryz, an opportunity that could have generated an additional $600 million to $800 million in revenue. "The status quo at Avadel is unacceptable," ASL told shareholders in its letter. The election for the directors will be held at the company's annual meeting on July 29. ASL also asked Avadel to hire an investment bank to monetize the value in Lumryz, adding that the drug could bring $500 million to $1 billion in revenue if approved for idiopathic hypersomnia, a condition that causes excessive sleepiness. The fund holds shares worth about $15 million in Avadel according to a Wall Street Journal report on Sunday. Avadel told Reuters on Monday that its board has "consistently engaged with its largest shareholders and proactively sought their perspectives". The company said it remains focused on unlocking the full value of Lumryz in narcolepsy and in future indications. Separately, Avadel said the U.S. Court of Appeals for the District of Columbia Circuit gave a favorable, opens new tab ruling in a suit brought by Jazz regarding the FDA's approval of Lumryz. The ruling affirms FDA's decision to state that Lumryz's once-nightly dosing is clinically superior to other similar treatments.